Therapeutic Antibodies
Total Trials
1
As Lead Sponsor
As Collaborator
0
Total Enrollment
280
NCT06274437
A Study of BND-35 in Participants With Advanced Solid Tumors
Phase: Phase 1
Role: Lead Sponsor
Start: Jun 2, 2024
Completion: Nov 30, 2027
Loading map...